These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28384634)

  • 21. Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.
    Ueda N; Shiraha H; Fujikawa T; Takaoka N; Nakanishi Y; Suzuki M; Matsuo N; Tanaka S; Nishina S; Uemura M; Takaki A; Shiratori Y; Yamamoto K
    Mol Oncol; 2008 Oct; 2(3):241-9. PubMed ID: 19383345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
    Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
    Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of des-gamma-carboxy-prothrombin after portal vein embolization in a cirrhotic patient with hepatocellular carcinoma.
    Sohda T; Iwata K; Anan A; Kunimoto H; Yotsumoto K; Yokoyama K; Morihara D; Takeyama Y; Shakado S; Osame A; Kora S; Ohishi J; Yamauchi Y; Noritomi T; Yoshimitsu K; Yamashita Y; Sakisaka S
    Clin J Gastroenterol; 2015 Oct; 8(5):330-4. PubMed ID: 26374567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
    World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
    Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
    Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
    Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
    Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
    Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma.
    Yuan LW; Tang W; Kokudo N; Sugawara Y; Karako H; Hasegawa K; Aoki T; Kyoden Y; Deli G; Li YG; Makuuchi M
    Oncol Rep; 2004 Aug; 12(2):269-73. PubMed ID: 15254687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.
    Koike Y; Shiratori Y; Sato S; Obi S; Teratani T; Imamura M; Yoshida H; Shiina S; Omata M
    Cancer; 2001 Feb; 91(3):561-9. PubMed ID: 11169939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma.
    Tanaka T; Taniguchi T; Sannomiya K; Takenaka H; Tomonari T; Okamoto K; Kitamura S; Okahisa T; Tamaki K; Mikasa H; Suzuki S; Takayama T
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1348-55. PubMed ID: 23432345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
    Li GJ; Chen QY; Harrison TJ; Wang XY; Hu LP; Yang QL; Li KW; Fang ZL
    Cancer Biomark; 2017; 18(3):241-248. PubMed ID: 28085009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma.
    Zhang YS; Chu JH; Cui SX; Song ZY; Qu XJ
    Cell Physiol Biochem; 2014; 34(3):903-15. PubMed ID: 25200250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.
    Suzuki M; Shiraha H; Fujikawa T; Takaoka N; Ueda N; Nakanishi Y; Koike K; Takaki A; Shiratori Y
    J Biol Chem; 2005 Feb; 280(8):6409-15. PubMed ID: 15582995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
    Inoue S; Nakao A; Harada A; Nonami T; Takagi H
    Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway.
    Yue P; Gao ZH; Xue X; Cui SX; Zhao CR; Yuan Y; Yin Z; Inagaki Y; Kokudo N; Tang W; Qu XJ
    Eur J Cancer; 2011 May; 47(7):1115-24. PubMed ID: 21349701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes of plasma des-gamma-carboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K.
    Furukawa M; Nakanishi T; Okuda H; Ishida S; Obata H
    Cancer; 1992 Jan; 69(1):31-8. PubMed ID: 1309308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma.
    Cui SX; Yu XF; Qu XJ
    Cancer Invest; 2016 Oct; 34(9):459-464. PubMed ID: 27673353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
    Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
    Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
    Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
    Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population.
    Li J; Dou D; Li P; Luo W; Lv W; Zhang C; Song X; Yang Y; Zhang Y; Xu Y; Xiao F; Wei Y; Qin J; Li H; Yang X
    Tumour Biol; 2017 Jul; 39(7):1010428317706914. PubMed ID: 28714367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.